[Opportunistic infections in patients with collagen disease].
Tanaka
Yoshiya
Y
Saito
Kazuyoshi
K
D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D001424:Bacterial Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D002177:Candidiasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D003095:Collagen Diseases / Q000150:complications* / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D025202:Molecular Diagnostic Techniques; D009181:Mycoses / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D009894:Opportunistic Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D016720:Pneumocystis Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D016133:Polymerase Chain Reaction; D014376:Tuberculosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D014777:Virus Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents